Navigation Links
Lentigen Awarded $1.2 Million by U.S. Government Under the Qualifying Therapeutic Discovery Project

GAITHERSBURG, Md., Nov. 3, 2010 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery products, announced today that it will receive $1,235,306 in cash grants from the U.S. Government under the Patient Protection and Affordable Care Act.

Only companies with no more than 250 employees were eligible. Qualifying projects had to show reasonable potential to result in new therapies to treat areas of unmet medical need, prevent, detect, or treat chronic or acute disease and conditions, reduce long-term healthcare costs in the U.S., or significantly advance the goal of curing cancer within a 30-year period. 

In addition, preference was given to projects that showed the greatest potential to create and sustain high-quality, high-paying jobs in the U.S. and advance the country's competitiveness in the fields of life, biological, and medical sciences. Qualifying projects were eligible for either grants or tax credits.

"We are very pleased that 8 of the 9 applications that we submitted for review by the NIH and Treasury were approved and that the overall grant placed us among the top 5% of recipients in the nation. This provides further validation of our programs in cell therapies, vaccines and biotherapeutics," stated Tim Ravenscroft, CEO of Lentigen.  "As a small company operating in a difficult economic climate, these funds are very timely and will be invested in completion of our GMP manufacturing facility and the support of several of the therapeutic and vaccine programs submitted for consideration."

About Lentigen Corporation

Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vector technology for a wide range of therapeutic, vaccine, and bioproduction applications. Lentiviral vectors are the most efficient vehicles for the delivery of genes or gene silencing sequences stably into cells. Lentigen is a highly collaborative company, co-developing Lentiviral vector-based products across a broad spectrum of bench to clinical applications. Collaborations include The National Institutes of Health, PATH, IAVI, Harvard Medical School, Expression Therapeutics, Epixis SA, The University of Pennsylvania, The Johns Hopkins University, Case Western Reserve University, The Medical College of South Carolina, The University of Pittsburgh, the University of Minnesota, and The U.S. Army. For further information, visit

SOURCE Lentigen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Lentigen Awarded Phase I STTR Grant for Hunter Syndrome
2. Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
3. Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza
4. Lentigen Corporation Announces Relocation to New Facility
5. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
6. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
7. Omeros Corporation Awarded $1.7 Million in Grants Under the Qualifying Therapeutic Discovery Project Program
8. Federal nanotechnology renewal grant awarded to ASU faculty
9. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
10. LSU researchers awarded 1 of the largest NSF grants in Louisiana history
11. Vaccinex, Inc. Awarded Three Qualifying Therapeutic Discovery Project (QTDP) Grants Under the Patient Protection and Affordable Care Act of 2010 (PPACA)
Post Your Comments:
(Date:11/24/2015)... ... ... The United States Golf Association (USGA) today announced Dr. Bruce Clarke, of ... since 1961, the USGA Green Section Award recognizes an individual’s distinguished service to the ... of Iselin, N.J., is an extension specialist of turfgrass pathology in the department of ...
(Date:11/24/2015)... Mass. (PRWEB) , ... November 24, 2015 , ... ... to maintain healthy metabolism. But unless it is bound to proteins, copper is ... of Health (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic ...
(Date:11/24/2015)... , November 24, 2015 ... market research report "Oligonucleotide Synthesis Market by Product & ... Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & ... by MarketsandMarkets, the market is expected to reach USD ... 2015, at a CAGR of 10.1% during the forecast ...
(Date:11/24/2015)... , November 24, 2015 ... recent market research report released by Transparency Market Research, ... expand at a CAGR of 17.5% during the period ... Testing Market - Global Industry Analysis, Size, Volume, Share, ... global non-invasive prenatal testing market to reach a valuation ...
Breaking Biology Technology:
(Date:11/12/2015)... , Nov. 12, 2015  Arxspan has ... of MIT and Harvard for use of its ... information management tools. The partnership will support the ... biological and chemical research information internally and with ... be used for managing the Institute,s electronic laboratory ...
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , an ... of clinical research, is pleased to announce that it will ... Trials (PCT) event, to be held November 17-19 in ... to view live demonstrations of iMedNet , ... how iMedNet has been able to deliver time ...
(Date:11/10/2015)... 10, 2015 About signature ... helps to identify and verify the identity of ... as the secure and accurate method of authentication ... particular individual because each individual,s signature is highly ... when dynamic signature of an individual is compared ...
Breaking Biology News(10 mins):